EDUCATION

Undergraduate Degree

  • Yale University , 2007 , New Haven , CT

Medical School

  • Harvard Medical School , 2011 , Boston , MA

Internship

  • Brigham and Women's Hospital and Massachusetts General Hospital , 2012 , Boston , MA

Residency

  • Brigham and Women's Hospital and Massachusetts General Hospital , 2015 , Boston , MA

Fellowship

  • Brigham and Women's Hospital and Massachusetts General Hospital , 2019 , Boston , MA

CERTIFICATIONS

  • American Board of Genetics and Genomics
  • American Board of Medical Genetics and Genomics, Clinical Genetics
  • American Board of Obstetrics and Gynecology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Counseling for personal health implications identified during reproductive genetic carrier screening. Prenat Diagn. 2021 Oct; 41(11):1460-1466. View abstract
  2. Utility of noninvasive genome-wide screening: a prospective cohort of obstetric patients undergoing diagnostic testing. Genet Med. 2021 07; 23(7):1341-1348. View abstract
  3. Gene and Stem Cell Therapies for Fetal Care: A Review. JAMA Pediatr. 2020 10 01; 174(10):985-991. View abstract
  4. Fetal cardiac intervention-Perspectives from a single center. Prenat Diagn. 2020 03; 40(4):415-423. View abstract
  5. Noninvasive prenatal testing: from aneuploidy to single genes. Hum Genet. 2020 Sep; 139(9):1141-1148. View abstract
  6. Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery. Prenat Diagn. 2017 Jul; 37(7):640-646. View abstract
  7. Can enriching emotional intelligence improve medical students' proactivity and adaptability during OB/GYN clerkships? Int J Med Educ. 2015 Dec 26; 6:208-12. View abstract
  8. How Accurate Is the Dating of Scheduled 39-Week Deliveries? Am J Perinatol. 2016 Mar; 33(4):364-9. View abstract
  9. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am J Reprod Immunol. 2015 May; 73(5):437-44. View abstract
  10. How accurate is the dating of scheduled 39-week deliveries? Obstet Gynecol. 2014 May; 123 Suppl 1:55S. View abstract
  11. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9. View abstract
  12. Transitional cell carcinoma of the ovary: a case-control study. Gynecol Oncol. 2014 Mar; 132(3):649-53. View abstract
  13. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25. View abstract
  14. Uterine leiomyosarcoma: an updated series. Int J Gynecol Cancer. 2013 Jul; 23(6):1036-43. View abstract
  15. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013 Apr; 129(1):69-73. View abstract
  16. Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy. Gynecol Oncol Case Rep. 2012; 4:23-5. View abstract
  17. The safety of multiple re-excisions after lumpectomy for breast cancer. Ann Surg Oncol. 2011 Dec; 18(13):3797-801. View abstract